Retatrutide: Complete Guide to Eli Lilly's Triple Agonist

If you've been following the weight loss medication space, you already know how much semaglutide and tirzepatide have changed the game. But there's a new compound in the pipeline that could make both of those drugs look like warm-up acts. It's called retatrutide, and it's Eli Lilly's next-generation triple receptor agonist currently moving through Phase 3 clinical trials.

We've put together this complete guide to help you understand everything about retatrutide: what it is, how it works, what the clinical data shows, and when you might be able to get it. Whether you're a patient exploring options or a clinician keeping up with the field, this is the resource you need.

What Is Retatrutide?

Retatrutide (also known by its development code LY3437943) is an investigational medication being developed by Eli Lilly and Company. It belongs to a new class of drugs called triple hormone receptor agonists, sometimes referred to as "tri-agonists."

What makes retatrutide different from everything else on the market or in development is that it activates three distinct hormone receptors at once:

GLP-1 (glucagon-like peptide-1) receptors -- the same target as semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda)
GIP (glucose-dependent insulinotropic polypeptide) receptors -- the same additional target used by tirzepatide (Mounjaro, Zepbound)
Glucagon receptors -- a completely new target not used by any approved weight loss medication

This triple-action approach is why researchers and clinicians are so excited. Each receptor plays a different role in metabolism, and by hitting all three at once, retatrutide appears to produce weight loss results that surpass anything we've seen before in clinical trials.

How the Triple Agonist Mechanism Works

To really understand why retatrutide is generating so much attention, you need to understand what each of these three receptors does and why activating all of them simultaneously creates such a powerful effect.

GLP-1 Receptor Activation: Appetite Suppression

GLP-1 is an incretin hormone your gut naturally produces after you eat. When retatrutide activates GLP-1 receptors, several things happen:

Appetite decreases significantly through direct action on brain hunger centers
Gastric emptying slows down, so food stays in your stomach longer and you feel full
Insulin secretion increases in response to meals, improving blood sugar control
Glucagon secretion from the pancreas decreases after meals

This is the same mechanism that makes semaglutide and other GLP-1 drugs effective. But with retatrutide, it's just one piece of a larger puzzle.

GIP Receptor Activation: Metabolic Enhancement

GIP is the other major incretin hormone. Its role in weight loss medication is a more recent discovery, and it's what sets tirzepatide apart from pure GLP-1 drugs. When GIP receptors are activated:

Insulin sensitivity improves, meaning your body uses insulin more efficiently
Fat storage patterns shift, potentially reducing visceral (belly) fat
The satiety signals from GLP-1 are amplified and reinforced
Lipid metabolism improves, with beneficial effects on cholesterol and triglycerides

The combination of GLP-1 and GIP is what makes tirzepatide so effective. Retatrutide includes both of these, plus the third component that no approved drug has yet.

Glucagon Receptor Activation: The Game Changer

Here's where retatrutide truly breaks new ground. Glucagon is a hormone most people associate with raising blood sugar, which might seem counterintuitive for a weight loss drug. But glucagon does much more than that:

Increases energy expenditure: Glucagon receptor activation boosts your resting metabolic rate, meaning you burn more calories even at rest
Promotes fat oxidation: It signals your body to break down stored fat and use it as fuel
Reduces liver fat: Glucagon plays a key role in hepatic lipid metabolism, helping clear fat from the liver
Enhances thermogenesis: It increases heat production, which is another way your body burns calories

Think of it this way: GLP-1 and GIP work mainly on the "calories in" side of the equation by reducing appetite and improving how your body handles food. Glucagon works on the "calories out" side by ramping up how many calories your body burns. When you combine all three, you're addressing weight loss from every angle simultaneously.

Clinical Trial Results: The Evidence

The clinical data for retatrutide is, frankly, remarkable. Let's walk through what the trials have shown.

Phase 2 Trial Results

The Phase 2 trial results for retatrutide were published in the New England Journal of Medicine in 2023 and immediately made headlines.

Here are the key findings:

Participants: 338 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition
Duration: 48 weeks
Highest dose group (12 mg): Average weight loss of 24.2% of body weight
Middle dose group (8 mg): Average weight loss of 22.8%
Lower dose group (4 mg): Average weight loss of 17.5%
Placebo group: Average weight loss of 2.1%

To put 24.2% in context: that means a person weighing 250 pounds would lose about 60 pounds over 48 weeks. And the weight loss curves in the trial hadn't fully plateaued yet, suggesting even greater losses might be possible with longer treatment.

Phase 3 TRIUMPH Program Overview

Based on those Phase 2 results, Eli Lilly launched an extensive Phase 3 program called TRIUMPH (Triple Hormone Receptor Agonist Initiated in Participants with Unhealthy Weight for a Multi-faceted Program of Health). The program includes multiple trials:

Trial	Focus	Population	Status
TRIUMPH-1	Weight loss efficacy	Adults with obesity/overweight	Ongoing
TRIUMPH-2	Weight loss with type 2 diabetes	Adults with T2D and obesity	Ongoing
TRIUMPH-3	Weight maintenance	Adults who achieved initial weight loss	Ongoing
TRIUMPH-4	Metabolic health outcomes	Adults with obesity and cardiometabolic risk	Results reported
TRIUMPH-5	Long-term safety	Broad population	Ongoing

TRIUMPH-4 Results: 28.7% Weight Loss

The TRIUMPH-4 trial produced the most impressive results we've seen from any obesity medication in history.

Key findings from TRIUMPH-4:

Average weight loss: 28.7% at 68 weeks in the highest dose group
Participants losing over 15% body weight: Approximately 90%
Participants losing over 20% body weight: Approximately 75%
Participants losing over 25% body weight: Approximately 60%
Improvements in cardiometabolic markers: Significant reductions in blood pressure, triglycerides, HbA1c, and liver fat

A 28.7% average weight loss puts retatrutide in territory that previously could only be achieved through bariatric surgery. For a 250-pound person, that translates to roughly 72 pounds lost. And again, the weight loss trajectory had not fully plateaued at 68 weeks, suggesting longer treatment could yield even greater results.

How These Results Compare

To fully appreciate how remarkable these numbers are, let's compare retatrutide's results to other weight loss medications:

Medication	Mechanism	Average Weight Loss	Trial Duration
Semaglutide 2.4 mg (Wegovy)	GLP-1 agonist	~15%	68 weeks
Tirzepatide 15 mg (Zepbound)	GLP-1/GIP dual agonist	~22.5%	72 weeks
Retatrutide 12 mg	GLP-1/GIP/glucagon triple agonist	~28.7%	68 weeks

Each generation of these medications has represented a meaningful step forward. Semaglutide proved that pharmaceutical weight loss could be clinically significant. Tirzepatide showed that adding a second receptor could push results even further. And now retatrutide suggests that a third receptor could push us into what was once considered surgical territory.

Side Effects and Safety Profile

No medication is without side effects, and retatrutide is no exception. However, the side effect profile from clinical trials has been generally consistent with what we see from other incretin-based therapies, though with some important distinctions.

Common Side Effects

The most frequently reported side effects in retatrutide clinical trials are gastrointestinal in nature:

Nausea: Reported in 25-45% of participants (depending on dose), most common during dose escalation
Diarrhea: Reported in 15-25% of participants
Vomiting: Reported in 10-20% of participants
Constipation: Reported in 8-15% of participants
Decreased appetite: Reported frequently, though this is also a desired therapeutic effect
Injection site reactions: Mild reactions at the injection site in some participants

Most GI side effects were mild to moderate in severity and tended to decrease over time as the body adjusted to the medication, particularly after the dose escalation phase was complete.

Serious Adverse Events

Serious adverse events were relatively uncommon in clinical trials. Key safety findings include:

Rates of serious adverse events were similar between retatrutide and placebo groups
No signal for increased cardiovascular events
Liver enzymes were monitored closely, with retatrutide actually showing improvements in liver fat and liver enzyme levels in most participants
Cases of acute pancreatitis were rare and occurred at rates similar to other incretin-based therapies

Thyroid Considerations

Like all GLP-1 receptor agonists, retatrutide carries a boxed warning regarding thyroid C-cell tumors based on animal studies. In rodent studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). However, this finding has not been confirmed in humans despite years of GLP-1 drug use. Retatrutide is contraindicated in patients with:

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

For a more detailed breakdown of side effects and how to manage them, see our retatrutide side effects guide.

Dosing and Administration

Retatrutide is administered as a once-weekly subcutaneous injection, similar to semaglutide and tirzepatide. Based on the clinical trial protocols, here's what dosing looks like:

Dose Escalation Schedule

Like other incretin-based therapies, retatrutide uses a gradual dose escalation approach to minimize GI side effects:

Weeks	Dose	Purpose
Weeks 1-4	0.5 mg weekly	Initial tolerability
Weeks 5-8	1.0 mg weekly	Gradual increase
Weeks 9-12	2.0 mg weekly	Continued escalation
Weeks 13-16	4.0 mg weekly	Approaching maintenance
Weeks 17-20	8.0 mg weekly	Near-maintenance dose
Week 21+	12.0 mg weekly	Full maintenance dose

This slower escalation compared to some other medications helps the body adjust gradually and reduces the frequency and severity of nausea and other GI symptoms during the early weeks of treatment.

Administration Details

Injection frequency: Once weekly, on the same day each week
Injection sites: Abdomen, thigh, or upper arm (rotating sites recommended)
Timing: Can be taken at any time of day, with or without food
Missed dose: Clinical trial protocols generally allowed administration within a few days of the missed dose

FDA Timeline and Approval Predictions

One of the most common questions we hear is "when will retatrutide be available?" Here's what we know about the timeline:

Current Status (2026)

As of early 2026, retatrutide is in Phase 3 clinical trials. The TRIUMPH program is well underway, with several trials actively enrolling and others reporting results. Eli Lilly has not yet filed a New Drug Application (NDA) with the FDA.

Projected Timeline

Phase 3 trial completion: Expected throughout 2026, with key trials reporting results during the year
NDA submission: Most analysts project Eli Lilly will submit an NDA in late 2026 or early 2027
FDA review: Standard review takes approximately 10-12 months; priority review could shorten this to 6-8 months
Potential approval: Most optimistic estimates suggest late 2027; more conservative estimates point to 2028

It's worth noting that Eli Lilly has extensive experience navigating the FDA approval process. They successfully brought tirzepatide through approval for both diabetes (as Mounjaro) and obesity (as Zepbound), so they know the pathway well.

Factors That Could Affect the Timeline

Trial results: Strong safety and efficacy data could support a faster review
FDA priorities: The FDA has shown increased interest in obesity treatments, which could be favorable
Manufacturing readiness: Eli Lilly's ability to scale production will influence launch timing
Advisory committee review: The FDA may convene an advisory committee to review the data, which can add time

Cost Predictions

While we don't have official pricing for retatrutide (since it's not yet approved), we can make educated predictions based on comparable drugs.

Reference Pricing

Wegovy (semaglutide): List price approximately $1,300-$1,400 per month
Zepbound (tirzepatide): List price approximately $1,000-$1,100 per month

Given that retatrutide is a more complex molecule with superior efficacy data, analysts generally predict its list price will be in the range of $1,000-$1,500 per month. Eli Lilly may price it competitively with Zepbound to drive adoption, or they may price it at a premium given the superior clinical results.

For a deep dive on pricing, insurance coverage, and ways to save, check out our retatrutide cost article.

Retatrutide vs. Semaglutide vs. Tirzepatide

Let's compare the three most significant weight loss medications head to head.

Mechanism Comparison

Feature	Semaglutide	Tirzepatide	Retatrutide
GLP-1 receptor	Yes	Yes	Yes
GIP receptor	No	Yes	Yes
Glucagon receptor	No	No	Yes
Max weight loss (trials)	~15%	~22.5%	~28.7%
FDA approved	Yes	Yes	Not yet
Manufacturer	Novo Nordisk	Eli Lilly	Eli Lilly
Administration	Weekly injection	Weekly injection	Weekly injection

Efficacy Comparison

The jump from semaglutide to tirzepatide was roughly 7-8 percentage points of additional weight loss. The jump from tirzepatide to retatrutide appears to be another 6-7 percentage points. While these might sound like small numbers, in a 250-pound person, that's the difference between losing 56 pounds (tirzepatide) and 72 pounds (retatrutide).

The glucagon component in retatrutide is believed to be the primary driver of this additional benefit. By increasing energy expenditure and fat oxidation, retatrutide attacks excess weight from both sides of the energy balance equation, something that neither semaglutide nor tirzepatide can do.

Side Effect Comparison

The GI side effect profiles are broadly similar across all three medications, with nausea being the most common complaint. Some data suggests that the glucagon component of retatrutide may slightly increase the rate of certain GI side effects at higher doses, but the overall tolerability profile appears to be in the same range as tirzepatide.

Who Is Retatrutide For?

Based on the clinical trial enrollment criteria and the trajectory of similar drugs, retatrutide will likely be indicated for:

Primary Candidates

Adults with obesity (BMI 30 or higher) without additional health conditions required
Adults with overweight (BMI 27 or higher) who also have at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea

Potential Additional Indications

Eli Lilly may pursue additional indications beyond weight loss, including:

Type 2 diabetes: The TRIUMPH-2 trial is specifically studying retatrutide in patients with type 2 diabetes and obesity
MASH/NAFLD: The glucagon component's effect on liver fat makes retatrutide a promising candidate for metabolic-associated steatohepatitis (MASH), formerly known as non-alcoholic fatty liver disease
Cardiovascular risk reduction: Similar to how semaglutide gained a cardiovascular indication, retatrutide may pursue this pathway

Who Should Wait

If you're considering retatrutide, keep in mind that it's not yet available outside of clinical trials. In the meantime, proven options like semaglutide for weight loss and tirzepatide for weight loss are available and effective. Starting treatment now with an available medication and potentially switching to retatrutide when it becomes available is a reasonable strategy to discuss with your healthcare provider.

Retatrutide and Liver Health

One of the most exciting secondary findings from retatrutide trials involves its effects on liver fat. The glucagon receptor component appears to have a profound impact on hepatic lipid metabolism.

In clinical trials, participants treated with retatrutide showed dramatic reductions in liver fat content, with some studies measuring reductions of over 80% in liver fat at the highest doses. This has implications far beyond cosmetic weight loss. Fatty liver disease affects roughly one in three American adults, and currently there are very few effective pharmaceutical treatments.

Eli Lilly has initiated dedicated trials examining retatrutide specifically for MASH, which could eventually lead to an additional FDA indication beyond obesity.

What to Expect: A Realistic Timeline for Weight Loss

Based on clinical trial data, here's what a realistic weight loss trajectory looks like on retatrutide:

Weeks 1-4 (0.5 mg): Minimal weight loss, typically 1-2% of body weight. Your body is adjusting to the medication.
Weeks 5-12 (1.0-2.0 mg): Weight loss begins to accelerate. Most people notice reduced appetite and smaller portion sizes. Expect 3-5% total weight loss.
Weeks 13-24 (4.0-8.0 mg): This is where meaningful weight loss kicks in. The triple agonist mechanism is now fully active. Expect 10-15% total weight loss.
Weeks 25-48 (8.0-12.0 mg): Continued significant weight loss. Most participants in trials had lost 20-25% of their body weight by this point.
Weeks 49-68 (12.0 mg): Weight loss continues but at a slower pace. Average total weight loss in the TRIUMPH-4 trial reached 28.7% at 68 weeks.

Individual results will vary. Some people respond more dramatically, while others may see more modest results. Factors that influence response include starting weight, genetics, adherence to the medication, diet, and physical activity levels.

Diet and Exercise While Taking Retatrutide

While retatrutide powerfully reduces appetite and increases metabolism, lifestyle factors still matter. Clinical trial participants were generally encouraged to follow a reduced-calorie diet and increase physical activity. Here's our guidance:

Nutrition Recommendations

Prioritize protein: With significant weight loss, preserving muscle mass is critical. Aim for 0.7-1.0 grams of protein per pound of ideal body weight daily.
Stay hydrated: GI side effects like nausea and diarrhea can lead to dehydration. Aim for at least 64 ounces of water daily.
Eat nutrient-dense foods: Since you'll be eating less, make every bite count. Focus on vegetables, lean proteins, whole grains, and healthy fats.
Eat slowly: Slowed gastric emptying means eating too fast or too much can worsen nausea.

Exercise Recommendations

Resistance training: This is non-negotiable during significant weight loss. Strength training helps preserve lean muscle mass, which is essential for long-term metabolic health.
Cardiovascular exercise: Moderate cardio (walking, cycling, swimming) supports overall health and may enhance weight loss results.
Start gradually: If you haven't been exercising, start with walking and light resistance training. Build up over time.

Frequently Asked Questions

Is retatrutide available now?

No. As of early 2026, retatrutide is only available through clinical trials. It has not been approved by the FDA and is not commercially available. Some compounding pharmacies may claim to offer retatrutide, but these products are not verified and we strongly advise against using unverified sources.

How is retatrutide different from tirzepatide?

Both drugs are made by Eli Lilly. Tirzepatide is a dual agonist (GLP-1 and GIP), while retatrutide is a triple agonist (GLP-1, GIP, and glucagon). The addition of the glucagon receptor gives retatrutide its superior weight loss results by increasing energy expenditure and fat burning.

Will my insurance cover retatrutide?

It's too early to say definitively, but coverage will likely mirror what we've seen with tirzepatide and semaglutide. Many insurers are still reluctant to cover weight loss medications, though this is gradually changing as clinical evidence mounts and anti-obesity medications gain broader acceptance. For more details, see our retatrutide cost guide.

Can I take retatrutide with other medications?

Drug interaction data from clinical trials is still being analyzed. Like other incretin-based therapies, retatrutide slows gastric emptying, which can affect the absorption of certain oral medications. Your healthcare provider will review your complete medication list before prescribing.

Is retatrutide safe long-term?

Long-term safety data is still being collected through the TRIUMPH-5 trial and other studies. The medium-term data from Phase 2 and Phase 3 trials has been reassuring, with no unexpected safety signals. However, as with any new medication, we'll know more about long-term safety as post-market surveillance data accumulates after approval.

Will I regain weight if I stop taking retatrutide?

Based on what we know from semaglutide and tirzepatide, weight regain after discontinuation is common. This is because obesity is a chronic condition, and the biological drivers of weight regain (increased hunger hormones, reduced metabolic rate) return when the medication is stopped. The TRIUMPH-3 trial is specifically studying maintenance strategies, which should provide important guidance on this question.

The Bottom Line

Retatrutide represents the most significant advancement in pharmaceutical weight loss treatment we've ever seen. With average weight loss approaching 29% of body weight in clinical trials, it's entering territory that was previously reserved for surgical interventions.

The triple agonist approach, targeting GLP-1, GIP, and glucagon receptors simultaneously, addresses weight loss from multiple angles: reducing appetite, improving metabolic function, and increasing energy expenditure. The clinical data is compelling, the safety profile is manageable, and the potential additional benefits for liver health and cardiometabolic disease make this a truly exciting development.

That said, retatrutide is still investigational. We're likely still 18-24 months from FDA approval. If you're struggling with obesity now, don't wait. Effective treatments like semaglutide and tirzepatide are available today, and starting treatment now can improve your health while you wait for the next generation of options.

We'll continue to update this guide as new data emerges from the TRIUMPH program and as retatrutide moves closer to FDA approval. If you'd like to explore your current weight loss medication options, schedule a consultation with one of our physicians to discuss what's right for you.